Bavarian Nordic granted European approval of monkeypox vaccine

On Friday, the EMA’s expert committee recommended broadening the vaccine’s label, which already listed smallpox, to include monkeypox. The EU Commission has acted expeditiously, officially authorizing it today.

Photo: Bavarian Nordic / PR

On Monday, the EU Commission officially extended the indication of Bavarian Nordic’s smallpox vaccine, Imvanex, to also include monkeypox, the firm announced in a press release.

The Commission has thus acted fast on the recent positive opinion for the vaccine given by the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP). Only three days have passed since then, Friday.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs